Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02114957 · ClinicalTrials.gov registry record · Early Phase 1
Pharmacokinetics of Decursin/Decursinol Angelate (CognIQTM)
A Early Phase 1 study, sponsored by Texas Tech University Health Sciences Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT02114957 is a Early Phase 1 study that has completed, run by Texas Tech University Health Sciences Center. The registered enrollment target is 20 participants.
The verdict
NCT02114957, a Early Phase 1 study, has completed, sponsored by Texas Tech University Health Sciences Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study is to investigate how human bodies absorb and metabolize two herbal drugs. The information is critical for drug development and could not be obtained from any other studies using animals. The two herbal drugs are decursin and decursinol angelate (DA) which naturally exist in a traditional herb Angelica gigas Nakai (AGN). Preclinical and clinical studies indicated that AGN and decursin/DA were quite safe to animals and human.
Interventions
- DIETARY_SUPPLEMENT 800mg dietary supplement CognIQTM (4 capsules) by oral at hour 0
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02114957
The ClinicalTrials.gov registry entry for NCT02114957 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Texas Tech University Health Sciences Center, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 800mg dietary supplement CognIQTM (4 capsules) by oral at hour 0 is the first listed.
NCT02114957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02114957 about?
NCT02114957 is a clinical study titled "Pharmacokinetics of Decursin/Decursinol Angelate (CognIQTM)". This study is to investigate how human bodies absorb and metabolize two herbal drugs. The information is critical for drug development and could not be obtained from any other studies using animals. The two herbal drugs are decursin and decursinol angelate (DA) which naturally exist in a traditional...
What is the current status of trial NCT02114957?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2013-01.
What interventions are being tested in trial NCT02114957?
The interventions under investigation include: 800mg dietary supplement CognIQTM (4 capsules) by oral at hour 0 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02114957?
This trial is sponsored by Texas Tech University Health Sciences Center, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.